Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Control of autophagic cell death by caspase-10 in multiple myeloma.

Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM.

Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28.

2.

Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.

Michallet AS, Mondiere P, Taillardet M, Leverrier Y, Genestier L, Defrance T.

PLoS One. 2011;6(10):e25820. doi: 10.1371/journal.pone.0025820. Epub 2011 Oct 18.

3.

Betulinic acid inhibits autophagic flux and induces apoptosis in human multiple myeloma cells in vitro.

Yang LJ, Chen Y, He J, Yi S, Wen L, Zhao J, Zhang BP, Cui GH.

Acta Pharmacol Sin. 2012 Dec;33(12):1542-8. doi: 10.1038/aps.2012.102. Epub 2012 Oct 15.

4.

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.

Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ.

Mol Cancer Ther. 2016 Jan;15(1):60-71. doi: 10.1158/1535-7163.MCT-15-0488. Epub 2015 Dec 4.

5.

Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.

Zhang H, Chen J, Zeng Z, Que W, Zhou L.

Int J Mol Med. 2013 May;31(5):1127-34. doi: 10.3892/ijmm.2013.1299. Epub 2013 Mar 12.

PMID:
23503641
6.

Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.

Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1567-76. doi: 10.1007/s00280-013-2156-3. Epub 2013 Apr 10.

7.

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.

Gu H, Chen X, Gao G, Dong H.

Mol Cancer Ther. 2008 Aug;7(8):2298-307. doi: 10.1158/1535-7163.MCT-08-0186.

8.

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.

Ramírez-Labrada A, López-Royuela N, Jarauta V, Galán-Malo P, Azaceta G, Palomera L, Pardo J, Anel A, Marzo I, Naval J.

Clin Transl Oncol. 2015 Feb;17(2):121-32. doi: 10.1007/s12094-014-1201-y. Epub 2014 Jul 19.

PMID:
25037851
9.

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.

Toscani D, Palumbo C, Dalla Palma B, Ferretti M, Bolzoni M, Marchica V, Sena P, Martella E, Mancini C, Ferri V, Costa F, Accardi F, Craviotto L, Aversa F, Giuliani N.

J Bone Miner Res. 2016 Apr;31(4):815-27. doi: 10.1002/jbmr.2741. Epub 2015 Dec 14.

10.

[Multiple myeloma and autophagy].

Lamy L.

Med Sci (Paris). 2013 Aug-Sep;29(8-9):685-7. doi: 10.1051/medsci/2013298002. Epub 2013 Sep 5. French. No abstract available.

11.

Autophagy induced by FTY720 promotes apoptosis in U266 cells.

Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z.

Eur J Pharm Sci. 2012 Apr 11;45(5):600-5. doi: 10.1016/j.ejps.2011.12.014. Epub 2012 Jan 20.

PMID:
22281442
12.

Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Follin-Arbelet V, Hofgaard PO, Hauglin H, Naderi S, Sundan A, Blomhoff R, Bogen B, Blomhoff HK.

BMC Cancer. 2011 Jul 18;11:301. doi: 10.1186/1471-2407-11-301.

13.

Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

Berg D, Stühmer T, Siegmund D, Müller N, Giner T, Dittrich-Breiholz O, Kracht M, Bargou R, Wajant H.

FEBS J. 2009 Dec;276(23):6912-27. doi: 10.1111/j.1742-4658.2009.07388.x. Epub 2009 Nov 6.

14.

IRF4 addiction in multiple myeloma.

Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM.

Nature. 2008 Jul 10;454(7201):226-31. doi: 10.1038/nature07064. Epub 2008 Jun 22.

15.

Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells.

Kauntz H, Bousserouel S, Gossé F, Raul F.

Apoptosis. 2011 Oct;16(10):1042-53. doi: 10.1007/s10495-011-0631-z.

PMID:
21779837
16.

Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.

Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B, Chen X.

Clin Cancer Res. 2011 May 15;17(10):3248-58. doi: 10.1158/1078-0432.CCR-10-0890. Epub 2011 Feb 2.

17.

Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.

Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S317-29. doi: 10.1016/j.clml.2013.05.019. Epub 2013 Aug 27.

18.

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.

Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M.

Mol Cancer Ther. 2012 Dec;11(12):2600-9. doi: 10.1158/1535-7163.MCT-12-0605. Epub 2012 Sep 25.

19.

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.

Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS.

Leuk Res. 2011 Jun;35(6):821-30. doi: 10.1016/j.leukres.2010.12.010. Epub 2011 Jan 8.

PMID:
21216463
20.

Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.

Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A, López-Rivas A.

Leuk Res. 2010 Nov;34(11):1533-8. doi: 10.1016/j.leukres.2010.07.002. Epub 2010 Jul 27.

PMID:
20667592

Supplemental Content

Support Center